AI camera system could replace subjective ratings for Drug-Induced movement disorders

NCT ID NCT07715994

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study is developing a computer-assisted tool that uses a camera to objectively measure movement problems caused by antipsychotic medications. Researchers will enroll 180 people—half with these movement disorders and half healthy—to see how well the tool's results match standard doctor assessments. The goal is to create a more consistent, automated way to diagnose and track conditions like drug-induced parkinsonism, akathisia, and tardive dyskinesia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could provide a more objective, reliable way to diagnose and monitor drug-induced movement disorders, improving patient care.
What could go wrong
This is an early-stage observational study. The tool may not match clinician assessments closely enough, and results may not generalize beyond this specific setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of a Control Group and an EPS Disease Group recruited at Shanghai Mental Health Center. Potential participants in the EPS Disease Group will be identified and screened by research physicians in relevant outpatient clinics, inpatient wards, and other institutionally approved recruitment settings. Participants in the Control Group may be recruited through institutionally approved notices or by study researchers. Eligibility will be confirmed according to the predefined inclusion and exclusion criteria. A total of 180 evaluable participants are planned, including 90 participants in the Control Group and 90 participants in the EPS Disease Group.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria A. Control Group 1. Aged 18 to 80 years, with no restriction on sex. 2. No current or past history of a psychiatric disorder meeting ICD-10 or DSM-5 criteria. 3. No current or past history of central nervous system disease, such as primary Parkinson's disease or epilepsy, and no severe physical illness. 4. No use within the 3 months before screening of medications that may cause extrapyramidal symptoms, such as antipsychotics or certain antiemetic medications. 5. Sufficient visual, auditory, and cognitive ability to understand and cooperate with the standardized device-side assessment task sequence. 6. Full understanding of the purpose and exploratory research nature of the study, voluntary participation, and provision of written informed consent. B. EPS Disease Group 1. Aged 18 to 80 years, with no restriction on sex. 2. Diagnosis of schizophrenia or a related psychotic disorder according to ICD-10 criteria. 3. Regular treatment with one or more antipsychotic medications for at least 4 weeks. 4. Clinically confirmed antipsychotic-induced extrapyramidal symptoms meeting at least one of the following criteria: 1. Drug-induced parkinsonism: a total score of 2 or higher on Items 1, 2, 3, 4, 5, and 9 of the Simpson-Angus Scale (SAS). 2. Akathisia: a score of 2 or higher on the Global Clinical Assessment item of the Barnes Akathisia Rating Scale (BARS). 3. Tardive dyskinesia: a score of 3 or higher on any one of Items 1 through 7 of the Abnormal Involuntary Movement Scale (AIMS), or a score of 2 or higher on any two of these items. 5. Sufficient visual, auditory, and cognitive ability to understand and cooperate with the standardized device-side assessment task sequence. 6. Full understanding of the purpose and exploratory research nature of the study, voluntary participation, and provision of written informed consent by the participant or, where applicable, the participant's legal guardian. Exclusion Criteria The following exclusion criteria apply to both groups: 1. Primary neurological or organic movement disorders that may affect the assessment results, such as primary Parkinson's disease, Huntington's disease, Wilson's disease, or sequelae of stroke. 2. Severe musculoskeletal disease, recent fracture, limb disability, or other physical conditions that prevent completion of the required assessment tasks. 3. Acute exacerbation of psychiatric symptoms with severe agitation, impulsivity, stupor, or severe cognitive impairment that prevents safe and adequate cooperation with the assessment. 4. Severe deformity of the face or tested limbs, large dark-colored tattoos, or severe non-removable occlusion that may substantially interfere with computer-vision-based assessment. 5. Poorly fitting removable dentures or frequent compensatory oral movements that may interfere with objective assessment of orofacial movements. 6. Any condition that, in the investigator's judgment, may affect participant safety, substantially compromise data quality, or make the individual unsuitable for participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Akathisia, drug-induced are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shanghai mental health center

    Shanghai, China